Loading
A phase 1/2 trial of Cyclophosphamide, Fludarabine in ovarian cancer, run by Beijing Biotech, now recruiting.
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT07589543 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUALNK, Cyclophosphamide, Fludarabine. Conditions listed: Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum. No results are recorded here; the registry entry is the source.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.